Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
Given the newer ATA guidelines, what is your approach to the management of Hurthle cell carcinoma?
Related Questions
How do you evaluate and manage Rezdiffra (resmetirom)-induced abnormal thyroid function tests?
Are there specific populations with hypothyroidism for whom you would consider adding liothyronine to levothyroxine therapy, given observational data linking levothyroxine therapy alone to higher risks of dementia and mortality?
Would you recommend pharmacologic treatment with levothyroxine for a patient with subclinical hypothyroidism and CAD s/p stent placement even if the TSH is less than 10mIU/L, given a described association with reduced risk for major adverse cardiovascular events with treatment?
For patients on T4/T3 combination therapy for management of hypothyroidism is there an indication for monitoring T3 levels and if so, what is the appropriate timing (trough versus peak) given the pharmacokinetics of liothyronine?
How do you counsel patients that are positive for both stimulatory and inhibitory autoimmune thyroid markers (TRAb, TSI and TPO Ab) regarding their likelihood of flipping from hyperthyroidism to hypothyroidism?
Do you recommend completion thyroidectomy and RAIT in patients found to have unifocal minimally invasive follicular variant of papillary carcinoma on pathology after thyroid lobectomy?
Does solid/trabecular type papillary thyroid carcinoma pathology confer a higher risk of recurrence and warrant radioactive iodine ablation therapy?
Are you more likely to recommend medical management for obesity instead of bariatric surgery in patients with preexisting hypothyroidism, given a recent study showing increased risks of complications?
How do you counsel breastfeeding women on their limitations post radioactive iodine ablation for thyroid cancer treatment?
Does papillary thyroid cancer with extensive squamous differentiation require specialized treatment beyond RAI and TSH suppression?
